Chronic lymphocytic leukaemia in 2020: the future has arrived

Milne, Kate, Sturrock, Beattie and Chevassut, Timothy (2020) Chronic lymphocytic leukaemia in 2020: the future has arrived. Current Oncology Reports, 22. a36 1-9. ISSN 1523-3790

[img] Microsoft Word (DOCX) (Review)
Restricted to SRO admin only

Download (119kB)
[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (359kB)

Abstract

Purpose of Review
Chronic lymphocytic leukaemia is now recognised as a heterogenous disease with a variety of clinical outcomes. Here we summarise the way it is currently stratified according to genetic risk and patient characteristics and the treatment approaches used for these different subgroups.

Recent Findings
Certain patients appear to sustain MRD negativity after combination chemoimmunotherapy, leading to the suggestion that their CLL may be cured. However, 17p-deleted, p53-mutated or IGHV-UM subgroups are generally resistant to FCR, and much better responses are seen with ibrutinib and venetoclax, frequently inducing MRD negativity that hopefully will be translated into durable remissions.

Summary
Small molecule inhibitors have already revolutionised CLL treatment. Going forward, we anticipate their use in the majority of patients, early after diagnosis and with curative intent.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: R Medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
Depositing User: Timothy Chevassut
Date Deposited: 23 Jun 2020 07:06
Last Modified: 23 Jun 2020 09:45
URI: http://sro.sussex.ac.uk/id/eprint/92079

View download statistics for this item

📧 Request an update